Cerebra, a Winnipeg-based medical technology company advancing sleep disorder diagnostics, has entered into a contract with The Government of Manitoba under a Request for Supply Arrangement (RFSA) for the Provision of Diagnostic Services. Through the arrangement, Cerebra will work closely with the Province of Manitoba to reduce the backlog of diagnostic sleep studies caused by the Covid-19 pandemic. The contract is for one thousand in-home polysomnography (PSG) studies and will begin early 2023. Referred patients will be able to perform a complete PSG in the comfort of their homes, providing comprehensive information comparable to that collected in a sleep lab.
“Bringing the sleep lab to the home has many benefits,” says Patrick Crampton, President and Chief Operating Officer at Cerebra. “Combining the convenience of traditional in-home sleep apnea studies with the much more comprehensive sleep analysis of a PSG is a major step forward in expanding diagnostic capabilities for both patients and sleep specialists.”
“Sleep is such a vital component for overall health. Undiagnosed sleep disorders can increase an individual’s risk of diabetes, obesity, hypertension and heart disease. The pandemic has impacted sleep study wait lists much the same as other areas of our healthcare system. The opportunity to leverage locally developed technology to help Manitobans is a great example of the innovation ecosystem Manitoba is developing. We are honored and excited to begin helping Manitobans and these one thousand studies are a great start.”